Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EvoNext Holdings S.A. (EVE.SW)
CHF2.14
+0.10 (+4.90%)
CH SIX Healthcare Biotechnology
Address
Duggingerstrasse 23 4153
Reinach, CH
Reinach, CH
CEO
Gerhard Lobmaier
Website
evonextholdings.com
IPO
2005-05-03
ISIN CH1262055788
Also trades on
London Stock Exchange · 0QQJ.L (CHF)
Other OTC · ELVAF (USD)
Other OTC · ELVAY (USD)
Swiss Exchange · EVE.SW (CHF)
Description
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF2.14
+0.10 (+4.90%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
32.8K
Beta
-0.01
Float Shares
6.69M
Free Float %
92.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.73% | +15.00% | +40.82% | +50.00% | +66.27% | +70.37% | +6.98% | -90.07% | -97.02% | -99.05% | -99.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.14
DCF (Unlevered)
0.86
-59.9%
DCF (Levered)
0.78
-63.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-90.76
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%— Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-164.6% Q4'25: +98.1% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-203.5% Q4'25: -373.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q4'25: -27.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.40M
est: 14.23M (-33.9%)
|
8.75M
est: 9.71M (-9.9%)
|
6.85M
est: 6.80M (+0.7%)
|
8.93M
est: 7.56M (+18.2%)
|
11.60M
est: 12.07M (-3.9%)
|
7.54M
est: 7.68M (-1.8%)
|
9.88M
est: 12.30M (-19.7%)
|
15.54M
est: 15.21M (+2.2%)
|
9.44M
est: 12.56M (-24.9%)
|
—
est: 26.60M (-100.0%)
|
—
est: 32.66M (-100.0%)
|
60.90M
60.90M – 60.90M
+86.5% YoY
|
78.20M
78.20M – 78.20M
+28.4% YoY
|
| EBITDA |
-28.48M
est: -8.54M (-233.6%)
|
-33.46M
est: -5.83M (-474.2%)
|
-40.44M
est: -4.08M (-891.3%)
|
-25.79M
est: -4.53M (-469.0%)
|
-13.18M
est: -7.24M (-82.1%)
|
-20.60M
est: -4.61M (-347.0%)
|
-31.82M
est: -7.38M (-331.2%)
|
-34.52M
est: -9.13M (-278.3%)
|
-98.36M
est: -7.54M (-1,205.0%)
|
3.70M
est: -5.32M (+169.6%)
|
-678.4K
est: -6.53M (+89.6%)
|
-12.18M
-12.18M – -12.18M
-86.5% YoY
|
-15.64M
-15.64M – -15.64M
-28.4% YoY
|
| EBIT |
-35.42M
est: -8.54M (-314.8%)
|
-40.66M
est: -5.83M (-597.9%)
|
-45.57M
est: -4.08M (-1,016.9%)
|
-30.96M
est: -4.53M (-582.9%)
|
-21.03M
est: -7.24M (-190.5%)
|
-28.77M
est: -4.61M (-524.3%)
|
-40.42M
est: -7.38M (-447.8%)
|
-42.61M
est: -9.13M (-366.9%)
|
-102.94M
est: -7.54M (-1,265.8%)
|
1.05M
est: -5.32M (+119.7%)
|
-678.4K
est: -6.53M (+89.6%)
|
-12.18M
-12.18M – -12.18M
-86.5% YoY
|
-15.64M
-15.64M – -15.64M
-28.4% YoY
|
| Net Income |
-31.89M
est: -129.37M (+75.3%)
|
-35.97M
est: -136.76M (+73.7%)
|
-38.98M
est: -130.72M (+70.2%)
|
-29.21M
est: -48.68M (+40.0%)
|
-21.64M
est: -48.08M (+55.0%)
|
-29.87M
est: -65.51M (+54.4%)
|
-41.27M
est: -63.11M (+34.6%)
|
-43.37M
est: -72.12M (+39.9%)
|
-105.23M
est: -71.40M (-47.4%)
|
1.04M
est: -11.88M (+108.8%)
|
-652.7K
est: -8.04M (+91.9%)
|
18.03M
18.03M – 18.03M
+324.2% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
3.88M
est: 13.40M (-71.1%)
|
5.16M
est: 9.15M (-43.6%)
|
7.47M
est: 6.40M (+16.7%)
|
5.26M
est: 7.12M (-26.1%)
|
3.89M
est: 11.36M (-65.8%)
|
2.68M
est: 7.23M (-63.0%)
|
10.28M
est: 11.58M (-11.2%)
|
10.79M
est: 14.32M (-24.7%)
|
15.28M
est: 11.83M (+29.2%)
|
788.7K
est: 28.48M (-97.2%)
|
678.4K
est: 34.97M (-98.1%)
|
65.22M
65.22M – 65.22M
+86.5% YoY
|
83.74M
83.74M – 83.74M
+28.4% YoY
|
| EPS |
-18.86
est: -17.94 (-5.1%)
|
-18.86
est: -18.96 (+0.5%)
|
-20.21
est: -18.13 (-11.5%)
|
-9.48
est: -6.75 (-40.4%)
|
-7.50
est: -6.67 (-12.5%)
|
-9.49
est: -9.08 (-4.5%)
|
-11.72
est: -8.75 (-33.9%)
|
-10.13
est: -10.00 (-1.3%)
|
-19.50
est: -9.90 (-97.0%)
|
0.14
est: -1.65 (+108.5%)
|
-0.09
est: -1.11 (+91.9%)
|
2.50
2.50 – 2.50
+324.2% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.67M
OE per share TTM
-2.07
Owner's Yield
-97.15%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
46.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.00% | 27.6K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
7.21M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anne De Vos | Head of Sales | — | female |
| Astrid Schafer | Head of Innovation | — | female |
| Gerhard Lobmaier | Chief Operations Officer | — | male |
| Gianluca Antonio Ferrari | Chairperson | — | male |
| Luc Gruner | Executive Officer | — | — |
| Thomas Schneckenburger | Head of Investor & Corporation Relations | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EVE.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
